Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Testing Status of Dicyclohexylcarbodiimide M930062

 

CASRN: 538-75-0

Formula: C13-H22-N2

Synonyms/Common Names

  • Bis(cyclohexyl)carbodiimide
  • DCC

Known Uses

Widely used reagent in the chemical and pharmaceutical industries; increasing use in field of bioenergetics; stabilizing agent in elastomers, natural rubber, and many types of polyolefins, polyesters, resins, fibers, cellulose esters, etc.

Chemical Properties

Toxicity Effects (HSDB)

Short-Term Toxicity

  • 2 weeks (Topical Application)  (C93021)  Completed 
    • Rats: F344/N; Mice: B6C3F1
    • Dose: R&M: 0, 2, 6, 17, 50, OR 150 MG/ML; 5/SEX/SPECIES/GROUP.
  • 20 weeks (Topical Application)  (C93021B)  Completed 
    • GMM-09 (NIH Number: 07-4426)  (Peer Review Approval 08/28/2006A )
      Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)
    • Mice: Tg.AC (FVB/N) Hemizygous
    • Dose: FEMALE MICE: 0, 0.75, 1.5, 3, 6, 12 MG/KG; 10/GROUP.
  • 27 weeks (Topical Application)  (C93021C)  Completed 
    • GMM-09 (NIH Number: 07-4426)  (Peer Review Approval 08/28/2006A )
      Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)
    • Mice: P53 +/- (C57BL/6)
    • Dose: 0, 0.75, 1.5, 3, 6, OR 12 MG/KG; 15/GROUP.
  • 13 weeks (Topical Application)  (C93021)  Completed 
    • GMM-09 (NIH Number: 07-4426)  (Peer Review Approval 08/28/2006A )
      Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)
    • Rats: F344/N; Mice: B6C3F1
    • Dose: R: 0, 0.75, 1.5, 3, 6, OR 12 MG/KG M: 0, 1.5, 3, 6, 12, OR 24 MG/KG; 10/SEX/SPECIES/GROUP; 6 GROUPS.

Special Studies

  • Absorption Disposition Metabolism Elimination (Intravenous; Topical Application)  (S0663)  Completed 
    • Citation: Disposition of Dermally and Intravenously Administered [14C]Dicyclohexylcarbodlimide in Fischer 344 Rats and B6C3F1 Mice January 4, 1999
    • Male Rats: F344/N; Male Mice: B6C3F1; Male Rats: F344/N; Male Mice: B6C3F1
    • Dose: dermal: 0.3 mg/kg, 3 mg/kg (rats, protective appliance used); 0.7 mg/kg, 6.2 mg/kg (mice) IV: 0.3, 3 mg/kg (rats-indwelling jugular cannula); 0.4, 0.6 mg/kg (mice-lateral tail vein).

Genetic Toxicology

  • Micronucleus  (A45449)  Completed 
    • Citation: Witt, K.L., Tice, R.R., Shelby, M.D., Chhabra, R.S., and Zeiger, E. Induction of Micronucleated Erythrocytes in Rodents by Diisopropylcarbodiimide and Dicyclohexylcarbodiimide: Dependence on Exposure Protocol. Environ. Molec. Mutag. Vol. 33 (1999) 65-74
    • Rats: Fischer 344
    • Male Negative 
  • Micronucleus  (A63966)  Completed 
    • Citation: Witt, K.L., Tice, R.R., Shelby, M.D., Chhabra, R.S., and Zeiger, E. Induction of Micronucleated Erythrocytes in Rodents by Diisopropylcarbodiimide and Dicyclohexylcarbodiimide: Dependence on Exposure Protocol. Environ. Molec. Mutag. Vol. 33 (1999) 65-74
    • Mice: B6C3F1
    • Male Weakly Positive 
    • Female Weakly Positive 
  • Salmonella  (A46724)  Completed 
    •  Negative 

Organ Systems Toxicity

  • 4 days, 6 days, 8 days Immunotoxicity (Topical Application)  (IMM96015)  Completed 
    • Female Mice: B6C3F1
    • Dose: 0, .003, .006, .03, & .06% IN ACETONE (99.8%) FOR SENSITIZATION, & .1% FOR CHALLENGE IN THE MEST & .006, .03, .06, AND .1% FOR SENSITIZATION IN THE LLNA. 25% DNFB WAS USED AS THE POSITIVE CONTROL FOR SENSITIZATION, & .5% FOR CHALLENGE.